SCHEMBL1178799

SCHEMBL1178799

CCCc1cc(C(=O)O)nc(S(C)(=O)=O)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
HCAR2 Q8TDS4 4/20 0.41
HCAR3 P49019 2/20 0.36
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
ALOX15 P16050 2/20 0.35
TSHR P16473 2/20 0.35
HIF1A Q16665 2/20 0.35
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
MAPT P10636 2/20 0.35
BACE1 P56817 1/20 0.34
GLP1R P43220 1/20 0.34
HSD17B10 Q99714 2/20 0.33
BPTF Q12830 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1179309 0.87 HCAR2 (0.38) HCAR2HCAR3ALOX15TSHRHIF1A
SCHEMBL1179066 0.82 ALDH1A1 (0.45) KDM4ELMNASMN1; SMN2ALDH1A1NPSR1
SCHEMBL1178897 0.80 NOS3 (0.35) HCAR2HCAR3ALOX15TSHRHIF1A
SCHEMBL4444099 0.76 GLP1R (0.43) KDM4ECTSSCTSKLMNASMN1; SMN2
SCHEMBL9625844 0.73 GPR35 (0.44) KDM4EHCAR2ALOX15TSHRHIF1A
Hydrochloric Acid SCHEMBL10580491 0.73 ALOX15 (0.39) KDM4EHCAR2ALOX15TSHRHIF1A
SCHEMBL1178898 0.73 KDM4E (0.43) KDM4EHCAR2HCAR3ALOX15TSHR
SCHEMBL1178845 0.73 KDM4E (0.43) KDM4EHCAR2HCAR3ALOX15TSHR
SCHEMBL1179299 0.73 LMNA (0.58) KDM4EHCAR2HCAR3ALOX15TSHR
SCHEMBL4446017 0.73 LMNA (0.36) KDM4ECTSSCTSKLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217594-B1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-01-08 EP disclosed
US-8299086-B2 Pyrimidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-30 US disclosed
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US disclosed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-16 US disclosed
EP-2217594-A2 NOVEL PYRIMIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-08-18 EP disclosed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed
WO-2009057079-A2 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD KDM4E 1738/4885HCAR2 2134/4885HCAR3 2489/4885
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES TYMP, DPYD, ENTPD5 KDM4E 1861/4885HCAR2 1067/4885HCAR3 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.